Head-to-head evidence
Matsupexole (KDT-3594) vs Piribedil (Clarium)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: D2/D3 · full Parkinson's Disease pipeline
Matsupexole (KDT-3594)
Developed by Kissei Pharmaceutical
NCT03845387 · Phase 2 · completed
The study randomly assigned 74 participants to KDT-3594 or active treatment with pramipexole, but neither participants nor investigators were blinded. Its primary endpoint was the clinical MDS-UPDRS score at 12 weeks; because no results or statistical comparison are posted, whether this endpoint was met is unknown.
Piribedil (Clarium)
Developed by Desitin Arzneimittel GmbH
NCT01007864 · Phase 3 · completed
The trial randomized patients to piribedil or an active comparator, but only the outcomes assessor (not patients or investigators) was blinded, and the primary vigilance test showed no significant difference between piribedil and the comparator drugs.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Matsupexole (KDT-3594)'s landscape · Piribedil (Clarium)'s landscape